ADAL Inhibitors
ADAL inhibitors encompass a variety of chemical compounds that specifically target signaling pathways influencing the activity of ADAL. Rapamycin and Everolimus are quintessential examples that directly target mTOR, a pivotal kinase in the PI3K/AKT pathway, fundamental for the phosphorylation and stabilization of ADAL. These inhibitors, by acting on mTOR, not only impede the direct phosphorylation events necessary for ADAL activity but also modulate the intricate network of signaling that governs its functional state. Similarly, compounds like LY294002, Wortmannin, ZSTK474, and Triciribine operate upstream, focusing on PI3K and AKT, with the consequence of impeding the AKT-mediated activation of mTOR and subsequent effects on ADAL. Through their action, these inhibitors collectively ensure a comprehensive blockade of the PI3K/AKT/mTOR axis, thus indirectly precluding the activation of ADAL.
Complementing the effects of PI3K/AKT inhibitors, compounds like PD98059 and U0126 target the MEK enzyme within the MAPK/ERK pathway, a pathway known for its potential to engage in cross-talk with the PI3K/AKT/mTOR signaling cascade. This cross-talk is critical, as the MAPK/ERK pathway can influence mTOR activity and hence the functionality of ADAL. The inhibition of MEK by these compounds thereby contributes to the attenuation of ADAL activity by tempering the interplay between these converging pathways. Furthermore, Torin 1, Perifosine, PP242, and AZD8055 add additional layers of inhibition, with Torin 1 and AZD8055 exhibiting selective inhibition of both mTORC1 and mTORC2 complexes, and Perifosine and PP242 hindering AKT activation. These inhibitors, through their targeted action, serve to comprehensively disrupt the signaling networks that facilitate ADAL activity, culminating in a robust inhibition of ADAL's functional state, without resorting to general pathway deactivation or nonspecific modulation. Thus, the suite of ADAL inhibitors, through their targeted and specific actions on distinct yet interrelated signaling molecules and pathways, ensures a concerted decrease in ADAL activity, shedding light on the intricate regulatory mechanisms that govern its function.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin specifically inhibits mTOR (mammalian target of rapamycin), which is a downstream kinase in the PI3K/AKT pathway. As ADAL is hypothesized to be regulated by mTOR through phosphorylation events that affect its stability and function, inhibition of mTOR by Rapamycin would lead to decreased activity of ADAL. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphatidylinositol 3-kinases (PI3K), which play a significant role in the PI3K/AKT/mTOR signaling pathway. By inhibiting PI3K, LY294002 prevents the activation of AKT, subsequently reducing the phosphorylation and activation of downstream targets like mTOR, thus indirectly decreasing ADAL activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that operates via an irreversible binding mechanism, leading to inhibition of the AKT signaling pathway, which indirectly affects ADAL by reducing its phosphorylation and subsequent activation by mTOR. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. Since the MAPK/ERK pathway can cross-talk with the PI3K/AKT/mTOR pathway, inhibiting MEK can reduce the overall signaling through mTOR, thereby impacting ADAL function. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically inhibits AKT, blocking its downstream signaling. Inhibition of AKT leads to reduced mTOR activity, which in turn would decrease the phosphorylation and activity of ADAL. | ||||||
Perifosine | 157716-52-4 | sc-364571 sc-364571A | 5 mg 10 mg | $188.00 $327.00 | 1 | |
Perifosine is an alkylphospholipid that acts as an AKT inhibitor. By preventing AKT activation, perifosine would limit mTOR signaling and thus could indirectly reduce ADAL activity. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus is an mTOR inhibitor similar to Rapamycin. By directly inhibiting mTOR, Everolimus would lead to reduced ADAL activity as its function is thought to be downstream of mTOR signaling. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Torin 1 is a potent and selective mTOR inhibitor that can reduce mTORC1 and mTORC2 signaling. Inhibition of these complexes would subsequently lower ADAL activity due to decreased phosphorylation events. | ||||||
ZSTK 474 | 475110-96-4 | sc-475495 | 5 mg | $75.00 | ||
ZSTK474 inhibits PI3K, reducing AKT phosphorylation and subsequent mTOR activation. This decreased mTOR signaling would lead to a reduction in ADAL activity. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
PP242 is a selective inhibitor of mTOR kinase activity, distinct from Rapamycin. By inhibiting mTOR, PP242 would reduce the phosphorylation and activation of ADAL. | ||||||